Thank you for registering your account
Thanks for joining touchNEUROLOGY to hear about news and updates from across the Neurology community.
We’ve sent you an email to verify your email address. Please click on the link to confirm your account.
You can review your email preferences at any time or update your account details
Looking back over 2018: What have we learnt about optimizing the treatment of advanced Parkinson’s disease?
Watch a series of internationally renowned clinical specialists from Europe discuss pivotal data for Parkinson’s disease from key neurology congresses throughout 2018 and consider how these findings may affect clinical practice. The potential implications of these data for optimizing outcomes for patients with advanced Parkinson’s disease are explored from both global and regional perspectives.
- Summarize the latest clinical data for emerging treatment options and treatment delivery systems for the management of motor and non-motor symptoms of Parkinson’s disease.
- Discuss the use of biomarkers for the early identification of Parkinson’s disease, and to facilitate the use of neuroprotective agents.
- Describe the use of emerging targeted agents and therapeutic strategies to manage treatment side effects and maintain patient quality of life.
Can we reach our goals for seizure management in drug-resistant focal epilepsy?
Watch leading experts discuss aspects of the diagnosis and treatment of drug-resistant epilepsy, including up-to-date clinical data.
- Recognize the impact of recurrent seizures in patients with drug-resistant epilepsy
- Outline the challenges associated with current standard of care approaches in the management of patients with drug-resistant epilepsy
- Assess how emerging anti-epileptic drugs might address the unmet treatment needs in patients with drug-resistant focal epilepsy
Andrew Feigin and Ralf Reilmann, AD/PD 2021: The PROOF-HD Study
touchNEUROLOGY had the pleasure of meeting with Andrew Feigin (Department of Neurology, NYU Grossman School of Medicine, New York City, NY, USA) and Ralf Reilmann (Founding Director, George Huntington Institute, Münster, Germany), to discuss the clinical utility of pridopidine in Huntington’s disease, and the ongoing PROOF-HD study. The abstract entitled ‘The PROOF-HD Study: Pridopidine’s Outcome […]
Tobias Hartmann, AD/PD 2021: Diet and Nutritional Interventions for Dementia Progression
We had the great pleasure of meeting with Tobias Hartmann (Director and Professor of Experimental Neurology, DIDP, Saarland University, Saarbrücken, Germany) to discuss the diet and nutritional interventions in the progress from MCI to dementia. Part 2 of our discussion can be found here. The abstract entitled ‘ADCOMS: A Post-Hoc Analysis Using Data from the […]
Marwan Sabbagh, AD/PD 2021: Phase 2 MCLENA-1 Trial
TouchNEUROLOGY had the great pleasure of speaking with Marwan Sabbagh (Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA) to discuss the phase 2 MCLENA-1 clinical trial rationale, assessing lenalidomide in patients with mild cognitive impairment due to Alzheimer’s Disease. The abstract entitled ‘Rationale for the MCLENA-1: A Phase II Clinical Trial for the Assessment […]
Andrew Feigin, AD/PD 2021: Results from the Phase 2 SIGNAL Trial
We had the opportunity to meet with Andrew Feigin (Department of Neurology, NYU Grossman School of Medicine, New York City, NY, USA) to discuss the results from the phase 2 Huntington’s Disease trial of Anti-Semaphorin 4D Antibody Pepinemab (SIGNAL). The abstract entitled ‘Results of Phase 2 Huntington’s Disease Trial of Anti-Semaphorin 4D Antibody Pepinemab (SIGNAL) […]
Neuropathy Associated with Hereditary Transthyretin Amyloidosis—Diagnosis and Management
US Neurology. 2020;16(2):103–9 DOI: https://doi.org/10.17925/USN.2020.16.2.103
Hereditary transthyretin amyloidosis (hATTR) is a progressive life-threatening disease that typically presents as progressive sensorimotor polyneuropathy, restrictive cardiomyopathy, or a combination of both.1 Patients with hATTR-associated polyneuropathy (hATTR-PN) typically require assistance walking after 5–6 years, and die within 7–10 years from the onset of neuropathy.2 However, clinical manifestations of amyloidosis can affect other organs as well, including […]
Cenobamate for the Treatment of Focal Seizures
US Neurology. 2020;16(2):87–97 DOI: https://doi.org/10.17925/USN.2020.16.2.87
Epilepsy is a very common neurological disease, affecting more than 50 million people worldwide and 3.4 million people in the USA.1–3 Focal seizures, formerly partial-onset seizures, are the most common type, making up ≥60% of cases.4–6 Patients with epilepsy have an increased risk of morbidity and mortality, a decreased quality of life and are more likely […]
Olfaction in Parkinson’s Disease – A Clinical Approach
European Neurological Review. 2020;15(1):37–40 DOI: https://doi.org/10.17925/ENR.2020.15.1.37
Olfactory loss has been extensively studied in Parkinson’s disease (PD) and is now widely acknowledged as one of the major non-motor symptoms of the disease, which precedes the occurrence of clinical motor symptoms.1,2 It is found in around 90% of patients with PD,3–5 and has been considered as a supportive criterion in clinical PD diagnosis according to […]
Siponimod—A Selective Sphingosine-1-phosphate Modulator for Secondary Progressive Multiple Sclerosis
US Neurology. 2020;16(2):99–102 DOI: https://doi.org/10.17925/USN.2020.16.2.99
Multiple sclerosis (MS) is a chronic neuro-inflammatory condition estimated to affect over two million people worldwide. Several subtypes of MS have been described, and they are defined by their clinical phenotypes.1 The majority of patients initially exhibit relapsing remitting MS (RRMS), which is characterized by acute episodes of overt inflammation associated with abrupt clinical decline, most […]